Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19029599 | 0.82 | CYP2D6 (0.34) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL19052661 | 0.80 | METAP2 (0.34) | ALDH1A1ALOX15TDP1 | |
| SCHEMBL19029656 | 0.80 | CYP2D6 (0.38) | GAAALDH1A1KMT2A | |
| SCHEMBL19029407 | 0.80 | CYP2D6 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL19029592 | 0.79 | ALDH1A1 (0.39) | GAAALDH1A1KMT2A | |
| SCHEMBL473765 | 0.79 | SLC22A6 (0.34) | — | |
| SCHEMBL28172951 | 0.79 | GAA (0.41) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL12925787 | 0.79 | GAA (0.41) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL19052807 | 0.77 | UGT2B7 (0.33) | ALDH1A1 | |
| SCHEMBL16558808 | 0.75 | MGAM (0.55) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036472-A | Photocatalysis preparation method of milbelin intermediate | 山东新时代药业有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-118726496-A | Enzymatic preparation method of milbelin intermediate | 尚科生物医药（上海）有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-2719677-B1 | METHOD FOR PRODUCING BICYCLIC COMPOUND VIA CLAISEN REARRANGEMENT | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2412700-B1 | METHOD FOR PRODUCING BICYCLIC GAMMA-AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-09 | — | — | EP | disclosed |
| US-9206104-B2 | Methods for producing bicyclic compounds via iminium salt | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9162971-B2 | Methods for producing bicyclic compounds via claisen rearrangements | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-20 | — | — | US | disclosed |
| EP-2657219-B1 | Intermediate for producing bicyclic y-amino acid derivative | DAIICHI SANKYO CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2719676-A1 | METHOD FOR PRODUCING BICYCLIC COMPOUND VIA IMINIUM SALT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2719677-A1 | METHOD FOR PRODUCING BICYCLIC COMPOUND VIA CLAISEN REARRANGEMENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2657219-A1 | Intermediate for producing bicyclic y-amino acid derivative | Daiichi Sankyo Company, Limited (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-2192109-B1 | BICYCLIC -AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8324425-B2 | Method for producing bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20120071685-A1 | METHOD FOR PRODUCING BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2412700-A1 | METHOD FOR PRODUCING BICYCLIC GAMMA-AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-7947738-B2 | Bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2192109-A1 | BICYCLIC -AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | GLRA2, GLRB, BCAT1 | GAA 3064/4885MGAM 4020/4885SI 4276/4885 |
| US-20120071685-A1 | METHOD FOR PRODUCING BICYCLIC gamma-AMINO ACID DERIVATIVE | ADRA2A, GABRB2, ADRB2 | GAA 1160/4885MGAM 2495/4885SI 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.